Central actions of beta-adrenoceptor blocking drugs in man.
D000319:Adrenergic beta-Antagonists / Q000097:blood / Q000134:cerebrospinal fluid / Q000494:pharmacology*; D000818:Animals; D001008:Anxiety Disorders / Q000188:drug therapy; D001522:Behavior, Animal / Q000187:drug effects; D001921:Brain / Q000187:drug effects; D000882:Haplorhini; D006801:Humans; D006935:Hypercapnia / Q000503:physiopathology; D008297:Male; D008563:Membrane Lipids / Q000378:metabolism; D051379:Mice; D008881:Migraine Disorders / Q000188:drug therapy; D009043:Motor Activity / Q000187:drug effects; D011311:Pressoreceptors / Q000187:drug effects; D011433:Propranolol / Q000134:cerebrospinal fluid / Q000494:pharmacology; D011485:Protein Binding / Q000187:drug effects; D011618:Psychotic Disorders / Q000188:drug therapy; D051381:Rats; D011930:Reaction Time / Q000187:drug effects; D011984:Sensory Receptor Cells / Q000187:drug effects; D012890:Sleep / Q000187:drug effects; D013552:Swine; D014202:Tremor / Q000188:drug therapy
D000319:Adrenergic beta-Antagonists; D008563:Membrane Lipids; D011433:Propranolol